Greg Blyskal is the Executive Director of Broad Hollow Bioscience Park. He has worked in the bioscience field for over 30 years. Greg has a medical biology degree and an MBA in marketing with a minor in finance. He began his business career with a division of American Home Products and worked as a Product Manager in its medical diagnostic division. In 1987 he joined a start-up European biotech company, Dynal, with a leading product line in cell and protein magnetic separation. Greg was President of the U.S. subsidiary from 1989 to 2000, prior to the company being sold to Invitrogen for €300 million. Greg joined Broad Hollow Bioscience Park (BHBP), an economic development program to support early-stage bioscience companies, as the Executive Director in 2000 the year it opened its first facility on the campus of Farmingdale State College. BHBP is a collaboration between the State University of New York (SUNY) and Cold Spring Harbor Laboratory. In 2002 OSI Pharmaceuticals became the program’s anchor tenant and in 2008 BHBP opened its second facility. In 2011 the lease agreement with OSI was expanded with OSI’s new owner Astellas Pharma, however, a global restructuring by Astellas resulted in a 2014 buy-out of the lease agreement. In recent years, BHBP has recruited six new companies and is in the process of repurposing the original anchor facility with the goal of developing collaborative activities with the college’s sciences departments. BHBP is an integral part of the Long Island Regional Economic Development Council’s goal to expand biotech and foster the growth and development of well-paying industries for New York.